The past 1st and 2nd of June, the second Dutch Antisense Therapeutics Symposium (DATS) took place in Nijmegen. During the morning schedule a special session focused on the Dutch center for RNA therapeutics (DCRT) took place. There, Rob Collin gave a talk about the use of antisense oligonucleotides to modulate splicing as a therapeutic approach of inherited retinal diseases focusing on the example of Stargardt disease. After that, he also participated in the panel session together with other speaker which belongs to the DCRT.
The DCRT is a nonprofit consortium of the medical centers [Leiden University Medical Center (LUMC), Erasmus MC (Rotterdam) and Radboudumc (Nijmegen)] which aims to develop RNA-therapies for patients with very rare disorders. Rob Collin is member of the DCRT Board of Directors. More information about the DCRT can be found in this link: DCRT Dutch Center for RNA Therapeutics (rnatherapy.nl)